Compare IMKTA & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMKTA | PHAR |
|---|---|---|
| Founded | 1963 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | N/A |
| Metric | IMKTA | PHAR |
|---|---|---|
| Price | $69.81 | $17.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | ★ 114.5K | 27.2K |
| Earning Date | 02-05-2026 | 11-06-2025 |
| Dividend Yield | ★ 0.96% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.40 | 0.00 |
| Revenue | ★ $5,334,032,609.00 | $362,274,000.00 |
| Revenue This Year | N/A | $25.19 |
| Revenue Next Year | N/A | $4.47 |
| P/E Ratio | ★ $15.65 | $3,085.37 |
| Revenue Growth | N/A | ★ 26.78 |
| 52 Week Low | $58.92 | $7.50 |
| 52 Week High | $78.59 | $18.30 |
| Indicator | IMKTA | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 43.41 | 56.00 |
| Support Level | $67.92 | $16.55 |
| Resistance Level | $70.83 | $17.37 |
| Average True Range (ATR) | 1.51 | 0.67 |
| MACD | -0.09 | -0.04 |
| Stochastic Oscillator | 32.21 | 73.19 |
Ingles Markets Inc is a U.S.-based company that is principally engaged in operating a supermarket chain. The company operates the business in the southeast United States, mainly in Georgia, North Carolina, South Carolina, and Tennessee, with a few stores in Virginia and Alabama as well. The company locates its stores majorly in suburban areas, small towns, and neighborhood areas. It offers a broad range of goods, including food products, pharmacies, health and beauty care products, and general merchandise. The retail business contributes the majority of the company's revenue. The company's real estate ownership of a material portion of total stores enables it to generate rental income.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.